精巣腫瘍におけるProliferating Cell Nuclear Antigen(PCNA)および核小体形成体関連蛋白(AgNOR)の発現について

Abstract

PCNAおよびAgNORは精巣胚細胞腫瘍の増殖能を反映し, またパラフィン標本を用いて検討できる点より複合組織型においても各組織型の増殖能を個別に推測できる可能性をもっている。さらには増殖能と化学療法に対する感受性をも検討できる可能性をもち, 精巣腫瘍の特性解析上有用な指標のひとつになりうる

Immunohistochemical staining using the monoclonal antibody of proliferating cell nuclear antigen (PCNA) and argyrophilic nucleolar organizer region associated protein (AgNOR) staining were performed on 28 paraffin-embedded testicular tumors, and their correlation was assessed according to histological type, clinical staging and tumor markers. PCNA positive rates and AgNOR numbers in nuclei were 57.9%, 4.38 in seminomas, 63.4%, 5.79 in embryonal carcinomas, 37.7%, 2.63 in teratomas, 61.3%, 4.43 in yolk sac tumors, 79.5%, 7.12 in choriocarcinomas, and 20.9%, 3.03 in cells of the normal seminiferous tubule, respectively. In pure seminomas, the PCNA positive rates and AgNOR numbers of the stage II to III group (72.6%, 4.75) were higher than those of the stage I group (47.8%, 3.67), but there was no significant difference between the two groups. There was a significant correlation between PCNA positive rate and AgNOR number in all specimens (r = 0.76, p < 0.002). These findings indicate that PCNA and AgNOR are suitable indicators for proliferative activity of testicular tumors.